Exenatide changed diabetes care, then quietly exited.
If your doctor mentioned exenatide, Byetta, or Bydureon and you came here looking for current 2026 information, the answer is short and important. Both Byetta (twice-daily exenatide) and Bydureon BCise (weekly exenatide) are discontinued in the UK and most major markets. Byetta supplies ended in 2024. Bydureon supplies ran out after the UK Department of Health and Social Care issued a Medicines Supply Notification on 15 October 2025. Exenatide is no longer first-line therapy anywhere modern GLP-1 medicines are available.
🔑 Key Takeaways
- Exenatide was the first GLP-1 receptor agonist on the market, sold as Byetta from 2005 and as Bydureon from 2012.
- The molecule is a synthetic version of exendin-4, originally isolated from the saliva of the Gila monster lizard.
- Byetta is a 5 or 10 mcg twice-daily injection; Bydureon BCise is a 2 mg weekly extended-release suspension using PLG microspheres.
- Byetta supplies ended in 2024; Bydureon supplies ended in October 2025 in the UK after a formal Medicines Supply Notification.
- Patients on exenatide are being switched to semaglutide, dulaglutide, liraglutide, or tirzepatide depending on need.
- EXSCEL (n=14,752) showed exenatide ER was non-inferior for cardiovascular outcomes but did not show clear superiority over placebo.
What exenatide actually is
Start with the strange origin story. Exenatide is a synthetic 39-amino-acid peptide. The template molecule, exendin-4, was discovered in the venomous saliva of the Gila monster, a desert lizard native to the southwestern United States. Researchers noticed the lizard could go months without eating, then handle a huge meal without crashing its blood sugar. The peptide responsible turned out to share roughly 53% of its sequence with human GLP-1, but with one critical difference. Exendin-4 resists breakdown by the DPP-4 enzyme that destroys natural GLP-1 within minutes. That single quirk made the first injectable GLP-1 agonist clinically practical.
Exenatide reached the US market as Byetta in April 2005. It was the first GLP-1 receptor agonist ever approved for type 2 diabetes. Bydureon, the once-weekly version, followed in 2012, then Bydureon BCise, the autoinjector pen, replaced it in 2017.
Byetta vs Bydureon BCise: formulation differences
Same molecule, two completely different dosing experiences.
| Feature | Byetta (IR) | Bydureon BCise (ER) |
|---|---|---|
| Frequency | Twice daily | Once weekly |
| Dose | 5 mcg, then 10 mcg | 2 mg fixed |
| Timing | Within 60 min before AM and PM meals | Any time, any day, with or without food |
| Delivery system | Multi-dose pen | Single-dose autoinjector |
| Carrier | Aqueous solution | PLG microspheres in medium-chain triglyceride |
| Storage | Refrigerate; in-use 30 days at room temp | Refrigerate; one-time room-temp use up to 4 weeks |
| HbA1c reduction | ~0.8% | ~1.4% |
| Steady-state plasma | ~10 weeks of weekly dosing | n/a |
The ER version uses a clever trick. Tiny biodegradable PLG (poly-lactide-co-glycolide) microspheres trap exenatide and release it slowly as the polymer hydrolyses. That gives a continuous low-level GLP-1 signal for a week from a single jab. Byetta, by contrast, gives two short pharmacokinetic peaks per day matched to meals, which is why it has stronger effects on after-meal glucose spikes and weaker effects on fasting glucose.
How exenatide works in plain language
Exenatide does four things at once:
- Tells the pancreas to release more insulin, but only when blood glucose is high. That glucose-dependent action is why exenatide alone rarely causes hypoglycemia.
- Suppresses glucagon, the hormone that tells the liver to dump sugar into the blood.
- Slows stomach emptying, which flattens after-meal blood sugar spikes and increases fullness.
- Acts on appetite centers in the brain, reducing food intake.
Average weight loss in the original phase 3 trials sat around 2 to 3 kg over 30 weeks. Modest by today's standards. For a fuller picture of how this class evolved, see our explainer on what GLP-1 actually is.
Why exenatide is no longer first-line
Modern GLP-1 medicines simply do more. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) deliver larger HbA1c drops and far larger weight reductions, with cardiovascular and kidney benefits backed by big outcome trials.
| Drug | Schedule | HbA1c drop | Average weight loss |
|---|---|---|---|
| Exenatide BCise | Weekly | ~1.4% | ~2 to 3 kg |
| Liraglutide (Victoza) | Daily | ~1.1% | ~3 kg |
| Dulaglutide (Trulicity) | Weekly | ~1.4% | ~3 kg |
| Semaglutide (Ozempic 1 mg) | Weekly | ~1.5% | ~4 to 6 kg |
| Semaglutide (Wegovy 2.4 mg) | Weekly | ~1.6% | ~15% body weight |
| Tirzepatide (Mounjaro 15 mg) | Weekly | ~2.1% | ~20% body weight |
SUSTAIN-3 directly compared semaglutide 1 mg to exenatide ER 2 mg over 56 weeks. Semaglutide produced a 1.5% HbA1c drop versus 0.9% for exenatide, and 5.6 kg weight loss versus 1.9 kg. The gap was clinical, not statistical.
Tirzepatide, a dual GIP/GLP-1 agonist, widened the gap even further. If you are deciding between current options, our breakdown of the best peptides for weight loss ranks them by real-world evidence, and our GLP-1 without insurance options guide covers cost workarounds.
What the discontinuation actually means
If you are still holding a Bydureon or Byetta prescription, this is the practical situation:
Discontinuation timeline you need to know
- Byetta: AstraZeneca discontinued the twice-daily pen during 2024. No commercial supply remains.
- Bydureon and Bydureon BCise: The UK DHSC issued a Medicines Supply Notification on 15 October 2025 confirming Bydureon 2 mg/0.85 mL prolonged-release pre-filled pens are discontinued. Stock in many regions ran out shortly after.
- Switching: Patients are typically moved to dulaglutide, semaglutide, liraglutide, or tirzepatide depending on insulin status, weight goals, and renal function.
- Why now: AstraZeneca cited a commercial decision. In practice, prescribers had largely shifted away from exenatide because semaglutide and tirzepatide outperform it on every meaningful endpoint.
Cardiovascular and kidney data: the EXSCEL trial
The big outcome trial for exenatide is EXSCEL, published in 2017. It enrolled 14,752 patients with type 2 diabetes, most with established cardiovascular disease, and ran for a median 3.2 years. Exenatide ER 2 mg weekly was non-inferior to placebo for major adverse cardiac events, but the superiority result missed statistical significance (HR 0.91, 95% CI 0.83 to 1.00, p=0.06). Compared with semaglutide (SUSTAIN-6), liraglutide (LEADER), and dulaglutide (REWIND), all of which hit clear cardiovascular superiority, exenatide ER landed in a weaker spot. That comparative weakness is part of why guidelines moved on.
Side effects you should still recognise
- Nausea is the most common side effect, especially during the first few weeks. Roughly 40% of Byetta starters report it; Bydureon is gentler because the dose ramps up slowly.
- Vomiting, diarrhea, constipation, and indigestion are next on the list.
- Injection-site nodules are very common with Bydureon BCise, occurring in around 10 to 20% of users. They are usually painless lumps that resolve over weeks.
- Acute pancreatitis is rare but listed as a class warning. Severe abdominal pain that radiates to the back warrants immediate medical attention.
- Risk of medullary thyroid carcinoma in animal models led to a boxed warning. Exenatide is contraindicated in anyone with a personal or family history of medullary thyroid cancer or MEN 2.
- Renal impairment can worsen because of dehydration from vomiting; not recommended below eGFR 30 mL/min/1.73 m².
- Hypoglycemia risk rises sharply when exenatide is combined with sulfonylureas or insulin.
Exenatide and Parkinson's disease
One reason exenatide kept generating headlines after newer GLP-1s overtook it is its potential neurological role. The Exenatide-PD3 phase 3 trial, published in The Lancet in early 2025, tested Bydureon 2 mg weekly in 194 people with Parkinson's disease over 96 weeks. The study did not find significant benefit on movement scores compared with placebo. Earlier phase 2 work had hinted at slowing of motor decline, so the negative phase 3 result was a real disappointment. Research into other GLP-1 agonists in Parkinson's continues, but exenatide itself is no longer the lead candidate.
Who actually still uses exenatide in 2026
Almost nobody as a fresh start. Realistically, the remaining users fall into three groups:
- Long-term patients in regions where last stocks were still being dispensed through early 2026 and a switching plan is now active.
- Clinical trial participants in non-diabetes indications such as neurodegeneration or polycystic ovary syndrome studies.
- Veterinary or pharmacology study contexts entirely outside this article's scope.
For anyone considering a GLP-1 today, the practical comparison is between semaglutide, tirzepatide, and the newer dual or triple agonists like retatrutide. If you want a current overview, our retatrutide peptide overview and the full list of peptides and uses are the right starting points. People specifically focused on weight outcomes often look at microdosing protocols rather than going back to older GLP-1s.
Switching off exenatide: what doctors are doing
- Bydureon weekly to semaglutide weekly: Stop Bydureon. Start semaglutide 0.25 mg weekly one week later, escalating per label. The long terminal half-life of exenatide ER (about 10 weeks of residual signal) means there is no withdrawal gap.
- Bydureon weekly to tirzepatide weekly: Same pattern. Start tirzepatide 2.5 mg weekly the week after the last Bydureon dose.
- Byetta twice daily to liraglutide daily: Stop Byetta in the morning. Start liraglutide 0.6 mg the next day, titrating weekly.
- Byetta to dulaglutide weekly: Direct switch the day after the last Byetta dose; start dulaglutide 0.75 mg weekly.
Cost note
Where supply still exists, Bydureon BCise list price has historically run around $850 per month in the US, with most patients paying under $50 with insurance. With the discontinuation, comparing newer GLP-1 cost options is more useful. Many switchers explore compounded tirzepatide or insurance pathways for branded versions.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Exenatide, Byetta, and Bydureon are prescription medications that have been discontinued in many regions. If you are currently taking exenatide or any GLP-1 receptor agonist, do not stop or switch medications without speaking to your prescriber. Discuss alternatives, side effects, and any medical history with a qualified clinician before making any treatment change.